×
About 7,025 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  2,328 results

The Duke Myasthenia Gravis Clinic Registry: II. Analysis of Outcomes.
https://doi.org/10.1002/mus.27794
Muscle & Nerve; Sanders DB, Lutz MW et. al.

Feb 4th, 2023 - The Duke Myasthenia Gravis (MG) Clinic Registry contains comprehensive physician-derived data on patients with MG seen in the Duke MG Clinic since 1980. The aim of this study was to report outcomes in patients seen in the Clinic and treated accord...

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04225871

Feb 3rd, 2023 - The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Feb 3rd, 2023 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

Kearns-Sayre Syndrome Masquerading as Myasthenia Gravis.
https://doi.org/10.1097/ICB.0000000000001397
Retinal Cases & Brief Reports; Sokol JT, Hoyek S et. al.

Feb 3rd, 2023 - Kearns-Sayre syndrome (KSS) is a mitochondrial DNA (mtDNA) deletion syndrome that is characterized by the triad of onset commonly before age twenty, pigmentary retinopathy, and chronic progressive external ophthalmoplegia. Here we present a case o...

Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of ...
https://doi.org/10.1097/CAD.0000000000001473
Anti-cancer Drugs; Wang CL, Zhao YZ et. al.

Feb 3rd, 2023 - The optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with re...

see more →

Guidelines  4 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critical...
https://doi.org/10.1097/CCM.0000000000002027
Critical Care Medicine; Murray MJ, DeBlock H et. al.

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

see more →

Drugs  74 results see all →

Clinicaltrials.gov  165 results

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04225871

Feb 3rd, 2023 - The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Comple...
https://clinicaltrials.gov/ct2/show/NCT05514873

Feb 3rd, 2023 - The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)

Rituximab for Anti-cytokine Autoantibody-Associated Diseases
https://clinicaltrials.gov/ct2/show/NCT01842386

Feb 3rd, 2023 - Anticytokine autoantibodies are an important and emerging cause of disease. Anticytokine autoantibody-associated diseases include disseminated nontuberculous mycobacterial infection caused by anti-interferon- >= autoantibodies, severe mucocutaneou...

A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05070858

Feb 2nd, 2023 - DBTP- Double blind treatment plan (24 weeks) ETP - Extension treatment plan (28 weeks) OLTP- Open label treatment plan (68 weeks) Off-treatment follow up period (52 weeks)

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05403541

Feb 1st, 2023 - The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 3...

see more →

News  219 results

Study evaluates features of alopecia areata in Hispanic/Latinx patients
https://www.mdedge.com/dermatology/article/260391/hair-nails/study-evaluates-features-alopecia-areata-hispanic/latinx
Doug Brunk

Dec 29th, 2022 - Among Hispanic/Latinx patients with alopecia areata, the mean age at diagnosis was 33 years, 24% had concomitant atopy, and 18% had one or more coexisting autoimmune conditions, most commonly rheumatoid arthritis. Those are among key findings from.

High Drug Costs Exclude Most Neurology Patients From Cutting-Edge Treatment
https://www.medscape.com/viewarticle/984953

Dec 2nd, 2022 - Because of high out-of-pocket costs of new-to-market neurologic drugs that are of similar benefit as older agents, only a small percentage of patients with neurologic disorders have access to these cutting-edge medications, new research shows. "Ou...

2022 Rare Neurological Disease Special Report
https://www.mdedge.com/neurology/article/258352/2022-rare-neurological-disease-special-report

Oct 15th, 2022 - INTRODUCTION Editor’s note By Glenn S. Williams Our 7th annual issue highlights several notable FDA approvals in 2021 and early 2022, emerging genetic therapies for monogenetic disorders, and recent advances in rare disease diagnosis and testing.

Myasthenia gravis: Finding strength in treatment options
https://www.mdedge.com/neurology/article/258351/rare-diseases/myasthenia-gravis-finding-strength-treatment-options
Peter Van Der Eb, Scarlet Toruno, MS et. al.

Oct 15th, 2022 - The term myasthenia gravis (MG), from the Latin “grave muscle weakness,” denotes the rare autoimmune disorder characterized by dysfunction at the neuromuscular junction. 1 The clinical presentation of the disease is variable but most often includes.

New Alzheimer's Trial Data; Microbiome and MS; Monkeypox's Neuro Complications
https://www.medpagetoday.com/neurology/generalneurology/100828

Sep 20th, 2022 - The oral beta-amyloid blocker ALZ-801 (valiltramiprosate) reduced plasma phosphorylated tau (p-tau181) by 41% and preserved hippocampal volume in a phase II study of Alzheimer's patients with an APOE4 allele, Alzheon announced. Investigational cre...

see more →

Patient Education  20 results see all →